Last reviewed · How we verify

NCT06769737

The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations

Not yet recruiting Phase 4 Last updated 10 January 2025
What this trial tests

Phase 4 trial testing Interventional group#1 in Spinal Anesthesia Evaluation in 75 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
15 August 2025
1 September 2025

Quick facts

Lead sponsorKing Abdulaziz Medical City
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment75
Start date1 March 2025
Primary completion15 August 2025
Estimated completion1 September 2025
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

King Abdulaziz Medical City — full company profile →

Who can join

Adults 18 to 80, any sex, with Spinal Anesthesia Evaluation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, double-blinded, randomized clinical trial aims to examine the effects of combining isobaric bupivacaine with dexmedetomidine administered intrathecally (IT), compared to the combination of isobaric bupivacaine administered intrathecally and dexmedetomidine administered intravenously (IV), on spinal anesthesia prolongation time in minutes, time of regression from Bromage score 3 to 0.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Anesthesia Evaluation

Currently open trials in the same condition.

Other King Abdulaziz Medical City trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06769737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing